OncLive TV

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Alessandro Gronchi, MD, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

Axel Grothey, MD, discusses combination therapies with regorafenib and trifluridine/tipiracil in colorectal cancer.

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.